CN106820151A - A kind of bivalve compound health composition, preparation method and application - Google Patents
A kind of bivalve compound health composition, preparation method and application Download PDFInfo
- Publication number
- CN106820151A CN106820151A CN201611200937.9A CN201611200937A CN106820151A CN 106820151 A CN106820151 A CN 106820151A CN 201611200937 A CN201611200937 A CN 201611200937A CN 106820151 A CN106820151 A CN 106820151A
- Authority
- CN
- China
- Prior art keywords
- bivalve
- compound
- health composition
- compound health
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 150000001875 compounds Chemical class 0.000 title claims abstract description 68
- 230000036541 health Effects 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000002775 capsule Substances 0.000 claims abstract description 26
- 238000009472 formulation Methods 0.000 claims abstract description 26
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 21
- 230000036039 immunity Effects 0.000 claims abstract description 16
- 239000003053 toxin Substances 0.000 claims abstract description 10
- 231100000765 toxin Toxicity 0.000 claims abstract description 10
- 230000002708 enhancing effect Effects 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims description 30
- 239000003826 tablet Substances 0.000 claims description 24
- 239000012467 final product Substances 0.000 claims description 23
- 239000004615 ingredient Substances 0.000 claims description 14
- 239000007910 chewable tablet Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 230000006870 function Effects 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 7
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 abstract description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 4
- 229930003268 Vitamin C Natural products 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 235000019154 vitamin C Nutrition 0.000 abstract description 4
- 239000011718 vitamin C Substances 0.000 abstract description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 8
- 239000003613 bile acid Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 235000013402 health food Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000011047 acute toxicity test Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003005 anti-senility effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to technical field of health care food, more particularly to a kind of bivalve compound health composition, by weight, the active component of the bivalve compound health composition includes following component：60 80 parts of shitosan；10 35 parts of chitosan oligosaccharide；10 15 parts of Se-enriched yeast；10 15 parts of xylo-oligosaccharide；25 parts of vitamin C；The formulation of said composition is tablet or capsule.Compound health composition in bivalve of the invention has functions that the enhancing immunity of organisms of protrusion and excludes vivotoxin, and long-term taking can improve immunity of organisms, exclude toxin, strengthen the ability of resist the disease；Meanwhile, said composition raw material is cheap and easy to get, and preparation method is simple, carries convenient to take.
Description
Technical field
The present invention relates to technical field of health care food, more particularly to a kind of bivalve compound health composition, preparation method and
Using.
Background technology
Improved due to China quality of life, dietary structure changes, and elderly population are just increased with annual 3% speed
It is long, cause various diseases to increase year by year therewith.With the improvement of living standards, people increasingly focus on the raising of quality of life,
Preventing and treating especially to the various diseases for having a serious harm has been raised to considerable position.
Therefore, develop new health food to improve immunity of organisms, the toxin of body accumulation is excluded, to prevent and subtract
The generation of few various diseases is highly significant.
The content of the invention
First purpose of the invention be to provide it is a kind of with strengthen immunity, toxin expelling the effects such as composition, for reality
Existing above-mentioned purpose, specifically adopts the following technical scheme that：
A kind of bivalve compound health composition, it is characterised in that：By weight, the bivalve compound health composition
Active component includes following component：
The weight portion is known in the art the unit of weights such as μ g, mg, g, kg, or is its multiple, and such as 1/100,1/10,10
Times, 100 times etc..
In above-mentioned composition, shitosan is unique positively charged natural animal fibres in nature, because shitosan is
Positively charged cationic compound, so being gathered in vivo around electronegative fat drips, forms barrier and hinders fat
Absorb, its absorption is reduced while it can also combine influence lipid emulsification with bile acid.Shitosan has promotion cholesterol to convert
Effect.Cholesterol is converted into bile acid in liver, and bile acid is the important component in digestive juice, there is certain storage in gall-bladder
Amount, bile acid generally after completing the digestion of fat and absorbing, is reabsorbed by small intestine and returns to liver, here it is " the intestines of bile acid
Liver is circulated ".Because shitosan is easily combined and all excreted with bile acid, then, in order to keep bile acid normal contents
Just cholesterol must be converted into bile acid in liver, the result is that the cholesterol level in blood necessarily declines, it may have aobvious
Write ground weight losing function.Shitosan has absorption vivotoxin, agricultural chemicals, heavy metal, chemical pigment, radioactive ray, is excluded in external；By force
Change liver function, suppress liver cancer disease hair；Alcoholic hepatitis, fatty liver, cirrhosis are worked well；Removal bad cholesterol, preventing and treating
Artery sclerosis, hypertension, headstroke；Hyperplasia enteral beneficial bacterium, promotes enterocinesia, eliminates effect of constipation.
Chitosan oligosaccharide, scientific name β-Isosorbide-5-Nitrae-oligosaccharides-gucosamine is that shitosan is obtained through special biological enzyme technology treatment
Water soluble shells widow's product, chitosan oligosaccharide is described as needed 6th vital principle of human body, with reinforced immunological, activating cell, suppression
Tumour, the liver function that improves, the aging, prevention disease that suppresses, promote disease recovery from illness, exclude internal cholesterol, exclude internal heavy metal,
Exclude toxin, the regulation function such as human physiological functions, or beneficial bacteria of intestinal tract (such as Bifidobacterium Bifidum) activation factor.Chitosan oligosaccharide quilt
21 century new " human body environment-friendly agent " is described as, its unique molecular structure imparts chitosan oligosaccharide physiologically active and work(higher
Energy.It has direct activation macrophage, NK cells, LAK cells, B and T lymphocytes, significantly increases immune function of human body, and
Cancerous swelling cell growth can be suppressed, promote liver spleen antibody to be formed, promote the absorption of calcium and mineral matter, propagation Bifidobacterium, lactic acid bacteria
Deng human body profitable strain, reducing blood lipid, hypotensive, hypoglycemic, regulation cholesterol, fat-reducing prevents the functions such as AD, can apply
In the field such as medicine and functional food.Multinomial research and clinical practice in recent years shows：Chitosan oligosaccharide is dissolved in stomach by hydrochloric acid in gastric juice
After form gel, diaphragm is formed on coat of the stomach, so as to prevent stimulation and corrosion of the hydrochloric acid in gastric juice to coat of the stomach.Chitosan oligosaccharide and stomach, 12
Duodenum 12 mucomembranous cell is affine, is acted on by activating cell, promotes impaired cell migration, is conducive to the healing of ulcer, and can increase
Plus in enteron aisle profitable strain quantity, suppress pernicious bacteria.Chitosan oligosaccharide in addition to suppressing in stomach and killing helicobacter pylori (HP),
Major part is absorbed and is utilized in small enteral, such that it is able to remove the various toxin being attached on intestinal villi, and promotes small intestine
Fine hair absorption function.Chitosan oligosaccharide is utilized in colon, and then safeguards the microecological balance in whole colon, fundamentally solves
The various diseases that colon causes because flora is unbalance, the healthcare function with strengthen immunity.
Preferably, the molecular weight of the chitosan oligosaccharide is 2000-10000Da.The chitosan oligosaccharide of this kind of molecular weight has increasing well
The function and security higher of strong immunity, during with other active components compounding use, are immunized and arrange with optimal enhancing
Toxic effect is really.
With chitosan oligosaccharide be applied in combination shitosan by the present invention, can strengthen immunity energy toxin expelling again, while product cost is low,
It is easy to be received by market.
In above-mentioned composition, the Se-enriched yeast is selenium source replenishers, and it can stimulate body to produce more immune globulin
The activity of white IgM and IgG, activating macrophage etc., strengthens body immunity.
Xylo-oligosaccharide is a kind of natural active matter, and sugariness is 0.3-0.6 times of sucrose, and it had both maintained the pure of sucrose
Sweetening characteristics, but it is salubriouser than sucrose sweet taste, and xylo-oligosaccharide, when being applied in terms of microorganism biological activity, has as new benefit rhzomorph
Very big prebiotics potentiality, optionally strengthen Bifidobacterium and are grown in enteron aisle, and beneficial bifid animalis bacillus
Growth, improve intestinal ecosystem, play its nutritional benefit in people's enteron aisle, meanwhile, xylo-oligosaccharide can improve calcium absorption and
The excretion of excrement calcium is reduced, xylo-oligosaccharide also contributes to the bioavilability of iron, can prevent hypoferric anemia.
Vitamin C is a kind of water miscible powerful antioxidant, is a kind of fabulous free radical scavenger, can protect biomembrane
Attacked from free radical, effective anti-senility nutrient, prevention of cardiovascular disease, and immunity of organisms can be improved, with the holding heart
Muscular function, the cholesterol reduced in blood, effectively set up etc. function.
Vitamin C is applied in combination with shitosan, can cooperate with and suppress digesting and assimilating for fat, helps to maintain body and is good for
Health.
Chitosan oligosaccharide of the present invention using molecular weight as 2000-10000Da as primary raw material, be more easy to be absorbed by biological cell and
Utilize, and using compound design, be aided with the shitosan with broad spectrum activity physiological function, xylo-oligosaccharide, nutrient prime replenisher selenium-rich
Yeast, powerful antioxidant vitamin C cooperates with strengthen immunity.While immunity of organisms is strengthened, enteron aisle work(can also be improved
Energy.
In a kind of optimal implementation method, the active component of the bivalve compound health composition includes following component：
The bivalve compound health composition can be prepared into conventional formulation using means well known in the art, such as
Granula, capsule, powder, tablet, pill etc..
Preferably, the formulation of compound health composition in bivalve of the invention is capsule or tablet, it is further preferred that institute
It is the one kind in coating tablet or chewable tablets to state tablet.
Said composition is prepared into above-mentioned capsule or tablet has and prepare advantage simple, easy to carry and use.
It is further preferred that present invention also offers the auxiliary material used when being prepared into above-mentioned formulation, being had using following auxiliary material
Help the preparation of formulation, preparation process is simple, the product for obtaining has good stability, and contributes to during taking
Active component is fully dissolved out.
Specifically, when the formulation is capsule, by weight, the bivalve compound health composition also includes
10-20 parts of starch, 0.5-1 parts of magnesium stearate.
When the formulation is chewable tablets, by weight, the bivalve compound health composition also includes 1-20 portions of milk
Powder, 0.5-1 parts of magnesium stearate, 1-10 parts of beta-schardinger dextrin, 1-2 parts of essence.
Wherein, the essence can use material well known in the art, present invention preferably employs fruit type essence, or mint type
Essence, or chocolate essence etc..
When the formulation is bag tablet, by weight, the bivalve compound health composition also includes 1-3 parts of bonding
Agent, 2-5 portions of disintegrant.
Preferably, described adhesive is starch, and the disintegrant is sodium carboxymethyl starch.Coating material can use this area
Known material.
Second object of the present invention is to provide the preparation method of above-mentioned any one bivalve composite heal-care food, the preparation
Method is specially：Each active component first is weighed according to proportioning, is mixed uniformly, obtain major ingredient, it is standby；Added in the major ingredient
The auxiliary material of corresponding formulation, specific formulation is prepared into according to corresponding formulation preparation method, is obtained final product.
Specifically,
When the formulation is capsule, preparation method comprises the following steps：
(1) major ingredient is prepared：Active component is weighed according to proportioning, then the active component is well mixed, obtained final product；
(2) compound is prepared：Major ingredient and auxiliary material are well mixed, after sterilizing, are obtained final product；
(3) bivalve compound health composition is prepared：By the filling capsule of the compound, capsule is obtained final product.
Preferably, chitosan oligosaccharide content >=350mg/g, chitosan content >=250mg/g in each capsule.
When the formulation is chewable tablets, preparation method comprises the following steps：
(1) major ingredient is prepared：Active component is weighed according to proportioning, then the active component is well mixed, obtained final product；
(2) compound is prepared：Major ingredient and auxiliary material are well mixed, after sterilizing, are obtained final product；
(3) bivalve compound health composition is prepared：The compound is pelletized, the particle that will be prepared is in 35-
After 45 DEG C of dryings, compressing tablet obtains final product chewable tablets.
Preferably, chitosan oligosaccharide content >=350mg/g, chitosan content >=250mg/g in each capsule.
When the formulation is tablet, preparation method comprises the following steps：
(1) major ingredient is prepared：Active component is weighed according to proportioning, then the active component is well mixed, obtained final product；
(2) compound is prepared：Major ingredient and auxiliary material are well mixed, after sterilizing, are obtained final product；
(3) bivalve compound health composition is prepared：The compound is pelletized, the particle that will be prepared is in 35-
After 45 DEG C of dryings, compressing tablet is coated, and obtains final product tablet.
Preferably, chitosan oligosaccharide content >=350mg/g, chitosan content >=250mg/g in each capsule.
Third object of the present invention is to provide above-mentioned any one bivalve compound health composition or using above-mentioned any
The bivalve compound health composition that a kind of method is prepared is preparing enhancing immunity of organisms and/or is excluding the guarantor of body toxin
Application in strong product or medicine.
Preferably, when the formulation is capsule, the mode of taking of the capsule is 1 tablet/time, 3 times/day, is taken daily.
When the formulation is chewable tablets, the mode of taking of the chewable tablets is 1 piece/times, 3 times/day, is taken daily.When the formulation is
During bag tablet, the mode of taking of the tablet is 1 piece/times, 3 times/day.
On the basis of common sense in the field is met, above-mentioned each optimum condition can be mutually combined, and obtain final product the present invention each preferably
Example.
The present invention relates to the commercially available acquisition of raw material and reagent.
The present invention achieves following good effect：Composition of the invention has good enhancing immunity of organisms, excludes
Effect of body toxin, long-term taking can improve immunity of organisms, exclude toxin, strengthen the ability of resist the disease；Meanwhile, the group
Compound raw material is cheap and easy to get, and preparation method is simple, carries convenient to take.
Specific embodiment
Following examples are used to illustrate the present invention, but are not limited to the scope of the present invention.The operation being related in embodiment
Unless otherwise specified, it is this area customary technical operation；
Embodiment 1
A kind of bivalve compound health composition, the formulation of the health food is capsule, and its active component is by following component
Composition：
Wherein, the molecular weight of the chitosan oligosaccharide is 2000-10000.
The auxiliary material of the bivalve compound health composition is：100kg starch and 10kg magnesium stearates.
The embodiment provides the preparation method of above-mentioned bivalve compound health composition simultaneously, specially：By above-mentioned activity
Composition is mixed according to weight input mixer, standby；To the auxiliary material is added in the active component for mixing, must mix after mixing
Material；Irradiation sterilization is carried out to the compound, it is filling under purification condition, obtain final product 2000 capsules；Capsule is dispensed, is wrapped
Dress, the qualified rear finished product storage of sampling inspection, obtains final product.
Embodiment 2
A kind of bivalve compound health composition, the formulation of the health food is chewable tablets, and its active component is by following component
Composition：
Wherein, the molecular weight of the chitosan oligosaccharide is 2000-10000.
The auxiliary material that the bivalve compound health composition is used is made up of following component：
The embodiment provides the preparation method of above-mentioned bivalve compound health composition simultaneously, specially：By above-mentioned activity
Composition is mixed according to weight input mixer, standby；To the auxiliary material is added in the active component for mixing, must mix after mixing
Material；The compound is carried out into irradiation sterilization, is pelletized, in 35~45 DEG C of dryings, compressing tablet obtains 2000 chewable tablets.
Embodiment 3
A kind of bivalve compound health composition, the formulation of the health food is tablet, and its active component is by following component group
Into：
Wherein, the molecular weight of the chitosan oligosaccharide is 2000-10000.
The auxiliary material that the bivalve compound health composition is used is made up of following component：
Starch 30kg
Sodium Hydroxymethyl Stalcs 40kg
The embodiment provides the preparation method of above-mentioned bivalve compound health composition simultaneously, specially：By above-mentioned activity
Composition is mixed according to weight input mixer, standby；To the auxiliary material is added in the active component for mixing, must mix after mixing
Material；The compound is carried out into irradiation sterilization, is pelletized, in 35~45 DEG C of dryings, compressing tablet, coating obtains final product 2000 tablets.
Comparative example 1
A kind of bivalve compound health composition, the formulation of the health food is capsule, and its active component is by following component
Composition：
Comparative example 2
A kind of bivalve compound health composition, the formulation of the health food is capsule, and its active component is by following component
Composition：
Wherein, the molecular weight of the chitosan oligosaccharide is 2000-10000.
Health product obtained in embodiment 1 is carried out into edible safety and Ergonomy test, foundation《Health food check with
Assessment technique specification (2003 editions)》Content is tested.
First, safety toxicology experiment
(1) acute toxicity test
1. sample：Sample prepared by formula and technique as described in embodiment 1.
2. experimental animal：SPF grades of Kunming mouse.
3. its mouse oral acute toxicity test (MTD)：From 18~22g SPF grades of Kunming mouse 20, male and female half and half,
With the oral secondary gavage of the dosage of 10g/kgBW, Continuous Observation 14 days after administration.Record poisoning manifestations and death condition.
4. result：With two kinds of mouse of sex of dosage gavage of 10g/kgBW, observe 14 days.Had no during experiment obvious
Poisoning manifestations, without death in the observation period.Tested material is all higher than 10g/ to two kinds of acute oral toxicities of the mouse of sex (MTD)
KgBW, according to《Toxicological evaluation of food safety procedure and method》(version in 2003) acute toxicity is classified, and belongs to nontoxic level, tool
Body is the results detailed in Table 1.
The acute toxicity tests of the sample mouse of table 1
| Sex | Approach | Number of animals (only) | Dosage (g/kgBW) | Death condition (only) | MTD(g/kg·BW) |
| It is male | Orally | 10 | 10 | 0 | >10 |
| It is female | Orally | 10 | 10 | 0 | >10 |
(2) 30 days feeding trials
1. sample：Sample prepared by formula and technique as described in embodiment 1.2. experimental animal：From 50~60g of body weight,
SD rats 60, male and female half and half.
3. test method：Rat is randomly divided into three tested material groups and a control group, every group 20, male and female half and half.
Control group is fed with arm's length basis block, and tested material group is then fed with mixing various dose sample, and dose design is：Low,
Middle and high dosage group is respectively 0.7,1.4,2.8g/kgBW (being respectively equivalent to 25 times, 50 times, 100 times that people intends with dosage).
Continuous Observation 30 days.
4. observation index and result
4.1 ordinary circumstances are observed：
Performance, behavior, toxicity performance and the death condition of animal are observed daily.Weigh weekly 1 time and food intake dose
Twice, food utilization and total food utilization weekly are calculated.As a result each group animal growth, activity are normal, without in
Poison performance and dead, each group animal body weight, weekly body weight evolution, weekly food-intake and food utilization weekly weekly, and always
Body weight evolution, total food-intake and the equal no difference of science of statistics (P of total foodstuff utilization rate>0.05).
4.2 hematological examinations：
Determine content of hemoglobin (Hgb), red blood cell (RBC) and leucocyte (WBC) to count, leukocyte differential count (lymph, list
Core, neutral grain, acidophilus, basophilic).Experiment latter stage hematological indices in range of normal value, each group animal blood red eggs
In vain, red blood cell and white blood cell count(WBC), the leukocyte differential count equal no difference of science of statistics (P compared with control group>0.05).
4.3 Biochemical Indexes：
Determine serum alanine aminotransferase (ALT), aspartate amino transferase (AST), urea nitrogen (BUN),
Cholesterol (CHO), triglycerides (TG), blood sugar (GLU), total protein (TP), albumin (ALB), creatinine (CRE).Experiment latter stage
In range of normal value, each group animal blood biochemistry index is compared with control group without statistics for experimental animal items biochemical indicator
Difference (P>0.05).
4.4 gross examination of skeletal muscle and pathologic diagnosis：
Experiment latter stage cervical dislocation puts to death animal, observes each main organs and chest, abdominal cavity general pathology change.Take out all
The liver of animal, kidney, spleen, testis, weigh and calculate organ coefficient.The liver of taking-up control group and high dose group animal,
Kidney, spleen, testis (or ovary), stomach and duodenum, use 12% formalin fix, and FFPE, section, HE are dyeed,
Histological examination is carried out under light microscopic.Each main organs (heart, liver, spleen, lung, kidney, stomach, intestines etc.) are showed no significant pathology and change
Become.
Above-mentioned acute toxicity test and 30 days feeding trial results show that this product belongs to nontoxic level, can be with long-term taking.
2nd, Ergonomy experiment
Difference orally administration mouse (Balb/c) 0.28g/kgbw, 0.56g/kgbw and 0.84g/kgbw is (respectively
10,20 and 30 times equivalent to human body recommended amounts) tested after the capsule 30d of embodiment 1 of dosage, as a result such as 2~table of table 5
It is shown.The glue of comparative example 1 of orally administration mouse (Balb/c) 0.84g/kgbw (equivalent to 30 times of human body recommended amounts) dosage
Tested after capsule 30d, as a result as shown in 2~table of table 5.Orally administration mouse (Balb/c) 0.84g/kgbw is (equivalent to people
30 times of body recommended amounts) dosage the capsule 30d of comparative example 2 after tested, as a result as shown in 2~table of table 5.
2.1 pairs of influences of mice serum hemolysin
Influence of the table 2 to mice serum hemolysin
Mice serum hemolysin test experiment in, 0.84g/kgbw dosage groups compared with control group mice, its antibody
Product has significant difference.
2.2 pairs of influences of the antibody-producting cell number of mouse
Influence of the table 3 to mouse hemolysis plaque number
In antibody tormation detection experiment, 0.84g/kgbw dosage groups are compared with control group mice, and its antibody tormation is thin
Born of the same parents' number has significant difference.
2.3 pairs of peritoneal macrophages of mouse swallow the influence of chicken red blood cell ability
Table 4 swallows the influence of chicken red blood cell to Turnover of Mouse Peritoneal Macrophages
In Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell experiment, 0.84g/kgbw dosage groups and 0.56g/kgbw
Compared with control group mice, phagocytic percentage, the phagocytic index of its peritoneal macrophage phagocytosis chicken red blood cell have aobvious to dosage group
Write sex differernce.
2.4 pairs of influences of the NK cytoactives of mouse
Influence of the table 5 to NK cytoactives
In the NK cytoactives experiment of mouse, the NK cytoactives of each dosage group mouse of sample are above negative control
Group, wherein high dose group have conspicuousness (P ＜ 0.05) with the difference of negative control group, show that the sample has and promote mouse
The effect of NK cytoactives.
According to the above results, understand that capsule of the invention has the function of strengthen immunity according to evaluation criterion.
Although above having used general explanation, specific embodiment and experiment, the present invention is made to retouch in detail
State, but on the basis of the present invention, it can be made some modifications or improvements, this is to those skilled in the art apparent
's.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to claimed
Scope.
Claims (10)
1. a kind of bivalve compound health composition, it is characterised in that：By weight, the work of the bivalve compound health composition
Property composition include following component：
Preferably, the molecular weight of the chitosan oligosaccharide is 2000-10000Da.
2. compound health composition in bivalve according to claim 1, it is characterised in that：The bivalve compound health composition
Active component include following component：
3. compound health composition in bivalve according to claim 1 and 2, it is characterised in that：The bivalve compound health group
The formulation of compound is capsule or tablet；
Preferably, the tablet is coating tablet or chewable tablets.
4. compound health composition in bivalve according to claim 3, it is characterised in that：When the formulation is capsule,
The bivalve compound health composition also includes auxiliary material, and by weight, the auxiliary material includes 10-20 parts of starch, and 0.5-1 parts hard
Fatty acid magnesium.
5. compound health composition in bivalve according to claim 3, it is characterised in that：When the formulation is chewable tablets,
The bivalve compound health composition also includes auxiliary material, and by weight, the auxiliary material includes 1-20 portions of milk powder, and 0.5-1 parts hard
Fatty acid magnesium, 1-10 parts of beta-schardinger dextrin, 1-2 parts of essence.
6. compound health composition in bivalve according to claim 3, it is characterised in that：When the formulation is coating tablet,
The bivalve compound health composition also includes auxiliary material, and by weight, the auxiliary material includes 1-3 parts of adhesive, 2-5 parts of disintegration
Agent；
Preferably, described adhesive is starch, and the disintegrant is sodium carboxymethyl starch.
7. the preparation method of the bivalve compound health composition described in claim 4, it is characterised in that comprise the following steps：
(1) major ingredient is prepared：Active component is weighed according to proportioning, then the active component is well mixed, obtained final product；
(2) compound is prepared：Major ingredient and auxiliary material are well mixed, after sterilizing, are obtained final product；
(3) bivalve compound health composition is prepared：By the filling capsule of the compound, capsule is obtained final product.
8. the preparation method of the bivalve compound health composition described in claim 5, it is characterised in that comprise the following steps：
(1) major ingredient is prepared：Active component is weighed according to proportioning, then the active component is well mixed, obtained final product；
(2) compound is prepared：Major ingredient and auxiliary material are well mixed, after sterilizing, are obtained final product；
(3) bivalve compound health composition is prepared：The compound is pelletized, the particle that will be prepared is in 35-45 DEG C
After drying, compressing tablet obtains final product chewable tablets.
9. the preparation method of the bivalve compound health composition described in claim 6, it is characterised in that comprise the following steps：
(1) major ingredient is prepared：Active component is weighed according to proportioning, then the active component is well mixed, obtained final product；
(2) compound is prepared：Major ingredient and auxiliary material are well mixed, after sterilizing, are obtained final product；
(3) bivalve compound health composition is prepared：The compound is pelletized, the particle that will be prepared is in 35-45 DEG C
After drying, compressing tablet is coated, and obtains final product tablet.
10. double described in bivalve compound health composition or any one of claim 7~9 described in any one of claim 1-6
Application of the shell compound health composition in the health products or medicine for preparing enhancing immunity of organisms and/or excluding body toxin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611200937.9A CN106820151A (en) | 2016-12-22 | 2016-12-22 | A kind of bivalve compound health composition, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611200937.9A CN106820151A (en) | 2016-12-22 | 2016-12-22 | A kind of bivalve compound health composition, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106820151A true CN106820151A (en) | 2017-06-13 |
Family
ID=59135674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611200937.9A Pending CN106820151A (en) | 2016-12-22 | 2016-12-22 | A kind of bivalve compound health composition, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106820151A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108065399A (en) * | 2017-12-29 | 2018-05-25 | 广州润虹医药科技股份有限公司 | A kind of health composition containing selenium and its application |
| CN109497557A (en) * | 2019-01-06 | 2019-03-22 | 宁波拜尔玛生物科技有限公司 | A kind of anti-Hp infection promotes composition and its application of stomach colony balance |
| CN111296759A (en) * | 2020-02-21 | 2020-06-19 | 广东正当年生物科技有限公司 | Composition with gastric mucosa protection function, application and preparation method thereof |
| CN112369607A (en) * | 2019-12-27 | 2021-02-19 | 青岛博智汇力生物科技有限公司 | Marine oligosaccharide food for protecting liver |
| CN117481345A (en) * | 2024-01-03 | 2024-02-02 | 四川如源科技有限公司 | Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1415310A (en) * | 2002-11-18 | 2003-05-07 | 安徽大学 | Nano selenium of chitin and its preparation method |
| CN1465285A (en) * | 2002-06-28 | 2004-01-07 | 中国科学院大连化学物理研究所 | Lead-removing health care food and preparation method thereof |
| CN103431392A (en) * | 2013-08-29 | 2013-12-11 | 青岛海百合生物技术有限公司 | Composite marine food for special dietary uses for diabetics |
| CN105194725A (en) * | 2015-10-16 | 2015-12-30 | 许盈 | Liquid bandage |
-
2016
- 2016-12-22 CN CN201611200937.9A patent/CN106820151A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1465285A (en) * | 2002-06-28 | 2004-01-07 | 中国科学院大连化学物理研究所 | Lead-removing health care food and preparation method thereof |
| CN1415310A (en) * | 2002-11-18 | 2003-05-07 | 安徽大学 | Nano selenium of chitin and its preparation method |
| CN103431392A (en) * | 2013-08-29 | 2013-12-11 | 青岛海百合生物技术有限公司 | Composite marine food for special dietary uses for diabetics |
| CN105194725A (en) * | 2015-10-16 | 2015-12-30 | 许盈 | Liquid bandage |
Non-Patent Citations (1)
| Title |
|---|
| 黄琬凌等: "免疫调节功能壳寡糖胶囊的研制", 《食品研究与开发》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108065399A (en) * | 2017-12-29 | 2018-05-25 | 广州润虹医药科技股份有限公司 | A kind of health composition containing selenium and its application |
| CN109497557A (en) * | 2019-01-06 | 2019-03-22 | 宁波拜尔玛生物科技有限公司 | A kind of anti-Hp infection promotes composition and its application of stomach colony balance |
| CN109497557B (en) * | 2019-01-06 | 2022-07-15 | 赵勤农 | Composition for resisting Hp infection and promoting gastric flora balance and application thereof |
| CN112369607A (en) * | 2019-12-27 | 2021-02-19 | 青岛博智汇力生物科技有限公司 | Marine oligosaccharide food for protecting liver |
| CN111296759A (en) * | 2020-02-21 | 2020-06-19 | 广东正当年生物科技有限公司 | Composition with gastric mucosa protection function, application and preparation method thereof |
| CN117481345A (en) * | 2024-01-03 | 2024-02-02 | 四川如源科技有限公司 | Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar |
| CN117481345B (en) * | 2024-01-03 | 2024-04-05 | 四川如源科技有限公司 | Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106820151A (en) | A kind of bivalve compound health composition, preparation method and application | |
| CN101606704B (en) | Dietary fiber food with various functional actions | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN104306617B (en) | Composition containing maca and A Sayi fruits and its preparation method and application | |
| CN101850002B (en) | Composition with function of improving nutritional anemia | |
| CN109451727A (en) | The composition and its preparation and application of probiotics and digestive ferment | |
| CN106998782A (en) | Diet fiber composition | |
| CN102077933A (en) | Special dietary seafood special for hyperuricemia patients | |
| CN113713084A (en) | Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people | |
| CN107951025A (en) | A kind of Chinese medicine health-care composition for health of losing weight | |
| CN101129351A (en) | Iron supplement composition, its preparing method and application of the same | |
| CN102423487A (en) | Osteoarticular health-care composition and its application | |
| CN101239091B (en) | Composition for preventing and controlling helicobacter pylori affection | |
| JP2022132561A (en) | Composition for preventing deterioration in sustained attention with aging | |
| EP2635130B1 (en) | Composition of purified soluble mannans for dietary supplements and methods of use thereof | |
| TW201332555A (en) | Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring | |
| CN110313599A (en) | A kind of anti-trioxypurine jelly and preparation method thereof | |
| CN101912407B (en) | Weight-reducing and lipid-lowering composition | |
| JP7091344B2 (en) | Prebiotic dietary supplements to promote amylose-degrading activity and activity of short-chain fatty acid-producing microorganisms | |
| CN104824511A (en) | Prebiotics composition | |
| JP3433917B2 (en) | Nutritional composition for enhancing body protein accumulation efficiency | |
| WO2014036655A1 (en) | Treatment of diarrhea and post-weaning diarrhea with resistant potato starch | |
| CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human | |
| CN104161746A (en) | Sugar-free lysine and gluconic acid zinc granule composition and preparation method thereof | |
| CN105050427A (en) | Edible composition, food product comprising same, and preparation method for the food product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170613 |